PR Newswire
ROCKVILLE, Md., Dec. 1, 2016
ROCKVILLE, Md., Dec. 1, 2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage
clinical company developing therapeutics focused on the gut microbiome, today announced that members of Synthetic Biologics'
executive leadership team will participate in two upcoming investor conferences:
2016 Jefferies Annual Microbiome Summit
London, England
Tuesday, December 13, 2016
Guggenheim Securities 4th Annual Boston Healthcare Conference
Boston, MA
Tuesday, December 13, 2016
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics focused on the gut
microbiome. The Company's lead candidates poised for Phase 3 development are: (1) SYN-010 which is intended to reduce the impact
of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation
(IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used
intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea (AAD) and
the emergence of antibiotic-resistant organisms. The Company is also developing preclinical stage monoclonal antibody therapies
for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria
(PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-announces-participation-in-two-upcoming-investor-conferences-300370677.html
SOURCE Synthetic Biologics, Inc.
